High-dose vaccine was significantly more effective in preventing postinfluenza deaths in 2012-2013, when A(H3N2) circulation was common, but not in 2013-2014.

No abstract

Background/Aim: National guidelines offer little guidance on the use of PSA progression (PSA increase as defined below) as a clinical endpoint in metastatic castrationresistant prostate cancer (mCRPC). The aim of the study was to examine treatment patterns/outcomes with abiraterone (abi)/enzalutamide (enza) throughout PSA progression and near the end of life (EOL). Patients and Methods: Cases of mCRPC treated with abi or enza from the New York Veterans Affairs (VA) from 6/2011-8/2017 were reviewed. Regression analyses were conducted to identify factors associated with continuation of abi/enza treatment up to the EOL, and survival. Results: Of 184 patients, 72 received abi alone, 28 received enza alone, and 84 received both. Treatment was changed for PSA progression alone in 39.1% (abi) and 25.7% (enza) of patients. A total of 37 patients (20%) received abi/enza within 1 month before death, 30% of whom were receiving hospice services. Older patients and black patients were less likely to receive abi/enza up to the EOL. Conclusion: Abi/enza are frequently discontinued for PSA progression alone and continued at EOL. The clinical benefit of these practices warrants additional study. Materials and Methods Study design. A multi-center, retrospective cohort study of patients with advanced prostate cancer at 2 participating VA medical centers (Manhattan, Brooklyn) was conducted to characterize abiraterone and enzalutamide treatment and patient outcomes. The study was approved by the institutional review board. Population and variables. A total of 184 patients with metastatic prostate cancer who received prescriptions for abiraterone acetate or 2467 This article is freely accessible online.

No abstract

No abstract